Clinical trials: Aggressive Behavior
Thyroid Cancer
This Study is Mainly About Finding Incidence Among Other Factors of Thyroid Cancer in Patient with Benign Disease As MNG to Early Discover of the Malignancy to Save the Patient from Aggressive Procedure
The purpose of the present study was to evaluate the prevalence of thyroid cancer in patients who had thyroidectomy for MNG, and analyze patient-related parameters to identify type and risk factors associated with incidental…
- Trial name
- NCT06730971
- Testing
- Total thyroidectomy
- Volunteers
- 300 people
- Sponsor
- Asmaa Mohamed Emam
Inflammatory Breast Cancer
Establishing an Inflammatory Breast Cancer Registry
Inflammatory breast carcinoma (IBC) is an extremely rare, aggressive form of breast cancer that disproportionately impacts young women.
- Trial name
- NCT00340158
- Where
- United States
- Volunteers
- 164 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed/Refractory Aggressive B-cell Lymphomas
Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas
This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 in participants with relapsed or refractory aggressive B-cell lymphomas who have failed 1-2 prior lines of therapy.
- Trial name
- NCT02271945
- Testing
- MEDI-551 12 mg/kg, MEDI0680 2.5 mg/kg, MEDI0680 10 mg/kg
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- MedImmune LLC
Aggression
Healthy Brains & Behavior: Understanding and Treating Youth Aggression
Understanding the joint neurobiological and social bases to aggression is critical to future attempts to tackle this major public health problem.
- Trial name
- HBB (NCT00842439)
- Testing
- CBI, NUT
- Where
- United States
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Meningioma, Meningioma Atypical
Predictive Factors for Survival in Aggressive Meningiomas
The investigators plan to collect clinical and molecular data, including ICH, PCR, NGS and methylome, from patients operated on for grade 2 or grade 3 meningioma.
- Conditions
- Meningioma, Meningioma Atypical, Anaplastic Meningioma
- Trial name
- 23Men (NCT05793034)
- Testing
- Biological biomarker assessment
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Symptomatic Intracranial Atherosclerotic Stenosis
Drug-Coated Balloon vs Aggressive Medical Management for High-Risk Symptomatic Intracranial Atherosclerotic Stenosis
DR.BEYOND-2 is an investigator-initiated, prospective, multicenter, randomized, open-label, blinded-endpoint, parallel-group clinical trial designed to evaluate the efficacy and safety of drug-coated balloon (DCB) angioplasty…
- Trial name
- DRBEYOND2 (NCT07830277)
- Testing
- Drug-Coated Balloon Angioplasty, Aggressive Medical Management
- Where
- 2 sites in China
- Volunteers
- 570 people
- Sponsor
- Beijing Tiantan Hospital
Mantle Cell Lymphoma
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma
This phase I/II trial studies the side effects and best dose of bortezomib when given with rituximab and chemotherapy drugs and to see how well they work in treating participants with mantle cell lymphoma.
- Trial name
- NCT00477412
- Testing
- Bortezomib, Cyclophosphamide, Cytarabine
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Non-Hodgkin
Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
Aggressive non-Hodgkin's lymphoma is difficult to handle once it relapses or becomes refractory to chemotherapy. Various second or third line chemotherapies, which are called salvage chemotherapy, were developed without promising…
- Trial name
- NCT00367497
- Testing
- Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin
- Where
- Japan
- Volunteers
- 5 people
- Sponsor
- Keio University
Lymphoma
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma
The goal of this clinical research study is to find the highest safe dose of AMG 531 that can be given to treat thrombocytopenia (low platelet counts) in patients who have received chemotherapy.
- Trial name
- NCT00299182
- Testing
- AMG 531, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Tourette's Syndrome, Attention Deficit Hyperactivity Disorder
Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD
In the present study, we examine the question "Will day-time aggression in children improve when their night-time sleep is treated with pharmacological intervention (i.e.
- Trial name
- NCT00152750
- Testing
- APO-clonidine
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Mental Health
Gender Microagression Psychoeducation
Objective: This study evaluates the effectiveness of the Gender-Based Microaggression Awareness and Prevention Psychoeducation Program, which was designed to enhance awareness of gender-based microaggressions among female…
- Trial name
- NCT07120360
- Testing
- Gender-Based Microaggression Awareness and Prevention Psychoeducation Program
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Yuzuncu Yil University
Bullying
KiVa Anti-bullying Program in Chile: Evaluation of Effectiveness With and Without the Digital Game Component
Bullying is a major problem worldwide and, with no exception, in Chile. Bullying is defined as a systematic aggressive behavior against a victim who cannot defend himself or herself.
- Trial name
- KiVa-Chile (NCT02898324)
- Testing
- KiVa program
- Volunteers
- 4,485 people, healthy volunteers welcome
- Sponsor
- Universidad de los Andes, Chile
Desmoplastic Small Round Cell Tumor, Synovial Sarcoma
Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
PAMSARC is a non-commercial interventional Phase 2 clinical trial of academic research institutions, with its primary goal being to improve medical treatment of fusion driven Desmoplastic small round cell tumor (DSRCT) and…
- Trial name
- PAMSARC (NCT06456359)
- Testing
- Signifor
- Where
- 4 sites in Germany
- Volunteers
- 28 people
- Sponsor
- University Hospital Heidelberg
Aggression, Anger
Group CBT for Aggression in Veterans
Posttraumatic stress disorder (PTSD) robustly predicts anger and aggression, and U.S. Iraq/Afghanistan-era combat Veterans report that treatment for anger and aggression is among their top priorities.
- Conditions
- Aggression, Anger, Posttraumatic Stress Disorder
- Trial name
- CBT-A (NCT02233517)
- Testing
- Cognitive Behavioral Therapy, Present Centered Therapy
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- VA Office of Research and Development
Breast Cancer
Clinical and Biological Study of Early-onset Breast Cancer and the Influence of the Reproductive Cycle on the Aggressiveness of the Disease
The incidence of breast cancer is increasing, particularly among young women. Cancers in young women are associated with a poor prognosis. The causes remain poorly understood.
- Trial name
- ARTEMIS (NCT07601152)
- Testing
- No Intervention: Observational Cohort
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Institut Cancerologie de l'Ouest
NHL, DLBCL
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
This is a Phase 1 platform protocol designed to evaluate various targeted agents for the treatment of relapsed/refractory aggressive Non-Hodgkin's Lymphoma (NHL).
- Conditions
- NHL, DLBCL, Non-hodgkin's Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- PRISM (NCT03527147)
- Testing
- AZD9150, Acalabrutinib, AZD6738
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Acerta Pharma BV
Depression, Anxiety
Efficacy of a Multi-level School Intervention for LGBTQ Youth
Efficacy of a Multi-level School Intervention for LGBTQ Youth
- Conditions
- Depression, Anxiety, Post Traumatic Stress Disorder, Coping Behavior
- Trial name
- NCT05541406
- Testing
- Proud & Empowered, Control Group
- Where
- 23 sites in United States
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell…
- Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Trial name
- NCT06238648
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- Academic and Community Cancer Research United
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
This clinical trial studies the side effects and best dose of giving fludarabine and total-body irradiation (TBI) together followed by a donor stem cell transplant and cyclosporine and mycophenolate mofetil in treating human…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00112593
- Testing
- fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Fred Hutchinson Cancer Center
Juvenile Idiopathic Arthritis
Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis
The objective of this study is to compare in very early polyarticular juvenile idiopathic arthritis (JIA) the efficacy, safety, and cost-benefit-ratio of three treatment strategies: biologic combination, combination of…
- Trial name
- ACUTE-JIA (NCT01015547)
- Testing
- Infliximab plus methotrexate, Combination of DMARDs, Methotrexate alone
- Where
- 6 sites in Finland
- Volunteers
- 60 people
- Sponsor
- Helsinki University Central Hospital